{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-264162","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.788349+00:00","generated_at":"2026-06-09T08:46:25.112143+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monte Rosa raises $25M via pre-funded warrant offering at $2.4999 per share","bullets":["Gross proceeds ~$25M from sale of pre-funded warrants to purchase 10,000,400 shares.","Offering price $2.4999 per warrant = Oct 25 closing price less $0.0001 exercise price.","Warrants immediately exercisable at $0.0001; 4.99% beneficial ownership cap (up to 19.99% at holder's election).","Net proceeds to advance pipeline: MRT-2359, MRT-6160 (VAV1 MGD), and NEK7 program.","Closing expected on or about Oct 30, 2023, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-264162","json":"https://secwatch.observer/filing/0001193125-23-264162.json","markdown":"https://secwatch.observer/filing/0001193125-23-264162.md","text":"https://secwatch.observer/filing/0001193125-23-264162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000119312523264162/0001193125-23-264162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000119312523264162/d512767d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T08:46:25.112143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5b05bad34470e777a67046ba038699db703305a0","claim":"Monte Rosa Therapeutics, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $25.0 million (effective 2023-10-26).","evidence_excerpt":"Monte Rosa Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors relating to the issuance and sale of pre-funded warrants to purchase 10,000,400 shares of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826457/000119312523264162/0001193125-23-264162-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"approximately $25.0 million"},{"label":"Effective","value":"2023-10-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}